Be the  leaner, healthier you

Weight loss Image Final

Lose up to 22%  Body Weight*

GPHC CQC Regulated

Weight loss Image Final

Lose up to 20% 
Body Weight*

Personalised Treatments, crafted just for you

Comprehensive Assessment

Comprehensive  Assessment

Our holistic approach starts with a comprehensive assessment of your health.

Evidence Based Approach

Evidence-Based  Approach

GLP-1 evidence-based weight loss treatment.*

Ongoing Support and Monitoring

Ongoing Support and Monitoring

Personalised support ensures success with tailored adjustments on your journey.

What awaits on your
Weight Loss path

Explore cutting-edge treatments,  crafted for
Men’s Wellness needs.

Today

Initial Assessment
Clinical Review
Prescribe GLP-1 Medication
Education and Support

1 - 6 months

Weight Loss Journey Begins
Appetite Suppression
Improved Blood Sugar Levels
Boosted Physical Activity

6 - 12 months

15% to 22% Weight Loss
Improved Metabolic Profile
Enhanced Well-Being
Embrace New Lifestyle

CUSTOMER IMPACT

Unlock your potential with evidence-based approach

Effective Weight Loss

Lose up to 22% body weight as seen in clinical trials.*

Improved Well-Being

Evidence demonstrates weight-related well-being improved after 68 weeks, including more energy and confidence.*

Healthier Heart

Over 9,000 participants in a clinical trial showed a significant increase in good cholesterol.*

TESTIMONIALS

Real Stories, Real Results:
Hear from Our Satisfied Customers

Latest reviews

FAQ

Your Weight Loss Journey Questions Answered

Our Weight Loss Treatment is designed for individuals struggling with overweight or obesity who are  seeking a safe and effective approach to weight loss. Our Treatment use GLP-1 receptor agonists (GLP-1  RAs) which have emerged as a promising therapeutic option for weight management, supported by  research demonstrating their efficacy in promoting significant and sustained weight loss along with diet  and exercise

GLP-1 receptor agonists are a class of medications that mimic the effects of a naturally occurring hormone  called glucagon-like peptide-1 (GLP-1). GLP-1 plays a role in regulating blood sugar and appetite. GLP-1 receptor agonists are currently available in two primary forms: weight loss injections and weight loss  tablets. We Injectable formulations have been established for some time, while a single oral GLP-1 receptor  agonist has recently been approved by the FDA. Examples of injectable GLP-1 receptor agonists include liraglutide (Saxenda) and semaglutide (Ozempic).   Rybelsus (semaglutide) is the first FDA-approved tablet for GLP-1 receptor agonist for weight mana

Our treatment utilizes injectable GLP-1 medications; Wegovy (semaglutide) and Mounjaro (tirzepatide).  both of which are approved by the MHRA (Medicines and Healthcare products Regulatory Agency) in the  UK for weight management. These medications are clinically proven to be effective for achieving and  maintaining weight loss. GLP-1 mimics a natural hormone in your gut. This hormone helps you feel full  for longer and improves how your body processes nutrients. As a result, you may experience reduced  appetite and boosted metabolism, contributing to weight loss. GLP – 1 medications offered by Priman are clinically validated to support weight loss. During your  consultation, your Priman clinician will conduct a thorough assessment to determine the most suitable  GLP-1 option for you
Yes, GLP-1 medications can cause side effects, although clinical trials indicate they are typically mild and  transient. A study of GLP-1 receptor agonists (GLP-1 RAs) for weight management highlights that gastrointestinal  side effects, particularly nausea, diarrhea, and constipation, are the most common. However, these  effects are generally mild and subside within the first week of treatment in most patients
References

*del Olmo-Garcia, M. I. and Merino-Torres, J. F. (2018) “GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes,” Journal of diabetes research, 2018, pp. 1–12. doi: 10.1155/2018/4020492.

*Lapid, N. (ed.) (2023) More weight loss with Mounjaro than ozempic: Data analysis, Medscape.

*Nauck, M. A. et al. (2021) “GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art,” Molecular metabolism, 46(101102), p. 101102. doi: 10.1016/j.molmet.2020.101102.

*Marso, S. P. et al. (2016) “Liraglutide and cardiovascular outcomes in type 2 diabetes,” The New England journal of medicine, 375(4), pp. 311–322. doi: 10.1056/nejmoa1603827.